Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: David Winkler who wrote (2764)	12/7/1998 9:06:00 AM
From: Terry D.	Read Replies (2) \| Respond to of 3702

TUSTIN, Calif.--(BUSINESS WIRE)--Dec. 7, 1998--Techniclone Corporation (Nasdaq:TCLN - news) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, announced today that the Company has begun treating the first patient in its Phase II multi-center human clinical study of its Tumor Necrosis Therapy (TNT) that is being investigated for the treatment of malignant glioma (brain cancer). The Phase II clinical study has a planned enrollment of 40 patients and the Company anticipates conducting this study at four clinical sites throughout the U.S.: The Medical University of South Carolina (MUSC), University of California, San Francisco Medical Center (UCSF), Temple University and University of Utah. As announced previously, Techniclone plans to recruit one-half of the study population from patients with newly diagnosed glioblastoma multiform (GBM) and the other half from patients with recurrent (GBM) or anaplastic astrocytoma (AA) in these Phase II trials. The protocol also allows patients to receive two doses administered eight weeks apart with dosage for each patient to be individualized based on a unique algorithm developed by Techniclone during the Phase I investigation, which was completed in October, 1998. ''We are very excited to be associated with four clinical centers which are worldwide renowned research organizations,'' stated Dr. Jamie Oliver, Vice President of Clinical and Regulatory Affairs. ''Additionally, the allowance to treat our first patients with newly diagnosed forms of glioblastoma represent significant milestones in the progress we have made with TNT.''